SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy
University of Trieste · The Royal Free Hospital · +20 more institutions
Indexed incrossrefpubmed
Abstract
Background
Transthyretin cardiomyopathy (ATTR-CM) was an exclusion criterion in randomized clinical trials of sodium-glucose cotransporter 2 inhibitors (SGLT2i).
Objectives
This study sought to assess the effectiveness and tolerability of SGLT2i in patients with ATTR-CM.
Citation impact
135
total citations
- FWCI
- 28.87
- Percentile
- 100%
- References
- 21
Citations per year
Authors
32- APAldostefano PorcariCorresponding
University of Trieste, The Royal Free Hospital, European Hospital, Azienda Sanitaria Universitaria Integrata di Trieste, University College London
- FCFrancesco Cappelli
Azienda Ospedaliero-Universitaria Careggi, University of Florence
- CNChristian Nitsche
Medical University of Vienna
- DTDaniela Tomasoni
University of Brescia
- GSGiulio Sinigiani
University of Padua
Topics & keywords
Topics
Keywords
- Medicine
- Transthyretin
- Amyloid (mycology)
- Cardiomyopathy
- Amyloidosis
- Internal medicine
- Cardiology
- Pathology
No related works found for this paper.